Clinical Trials Browser

Phase 1/2 × Triple Negative Breast Neoplasms × Cisplatin × Clear all

NCT02393794 2025-10-06

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03267316 2024-08-22

CANFOUR

Phase 1/2 Completed

BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2 Terminated

9 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT02983045 2023-03-13

PIVOT-02

Phase 1/2 Completed

557 enrolled 22 charts

BreastDermatologicGastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01031446 2018-08-31

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Phase 1/2 Completed

55 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01939418 2017-10-03

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

Phase 1/2 Terminated

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01918306 2017-06-27

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

Phase 1/2 Terminated

11 enrolled 12 charts

Breast Neoplasms, Triple Negative Breast Neoplasms